Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a Single Agent and in Combination in HLA-A*02:01-Positive Participants With Selected Advanced PIWIL1-Positive Cancers
Immunocore Ltd
600 participants
Jan 10, 2024
INTERVENTIONAL
Conditions
Summary
This phase 1/2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a single agent and in combination with other therapies in HLA-A\*02:01-positive participants with selected advanced PIWIL1-Positive cancers.
Eligibility
Inclusion Criteria7
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- HLA-A*02:01-positive
- Histologically confirmed advanced colorectal, esophageal, gastric, or ovarian carcinoma
- Archived or fresh tumor tissue sample that must be confirmed as adequate
- Evaluable/Measurable disease per RECIST 1.1
- Previously received applicable standard treatments
- Male and female participants of childbearing potential who are sexually active with a non-sterilized partner must agree to use highly effective methods of birth control
Exclusion Criteria10
- Symptomatic or untreated central nervous system metastasis
- Recent bowel obstruction
- Ongoing ascites or effusion requiring recent drainages
- Significant ongoing toxicity from prior anticancer treatment
- Out-of-range laboratory values
- Clinically significant lung, heart, or autoimmune disease
- Ongoing requirement for immunosuppressive treatment
- Significant secondary malignancy
- Hypersensitivity to study drug or excipients
- Pregnant or lactating
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
IV infusion
IV infusion
oral
oral
IV infusion
IV infusion
Locations(13)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06840119